ReviewInflammopharmacology2025
Unlocking the molecular pathway of atopic dermatitis: journey so far and roads ahead.
Review in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrative Transcriptomic, Network, and Genomic Analysis of Peripheral Blood Mononuclear Cells Identifies Candidate Genes Associated with Dupilumab Clinical Response in Atopic Dermatitis Patients.International journal of molecular sciences · 2026Article
- Targeting the JAK/STAT pathway in atopic dermatitis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic Dermatitis (AD) is a skin-associated disorder involving hyperactivation of inflammatory cascades. The attributing reasons to this include genetic predisposition, environmental factors and immunopathy. At the genetic level, there is an alteration in the filaggrin gene, which leads to impairment in the epidermal integrity. Hence, it makes the skin susceptible to irritants and allergens, causing skin barrier dysfunction, immune hypersensitivity and amplifying antigen penetration. However, at the molecular level the pathways altered in AD include T cell and cytokine pathway, Th2 pathways, IL pathway IL-4, IL-5, IL-13, Th1 pathway, IFN-γ cytokine pathway, Th17 pathway, IL-17 and IL-22 pathway, TGF-β pathway, JAK- STAT pathway, NFkB pathway, MAP2K2/ERK pathway, PI3K/Akt pathway, and Notch pathway. Overall, these events eventually lead to an increase in cytokine storm, keratinocytes proliferation, epidermal hyperplasia, fibrosis, oxidative stress and skin microbial imbalance. The present review highlights the molecular pathways associated with AD and discusses the crosstalk between inflammation, oxidative stress and genetic factors of AD. Moreover, understanding of these intricate pathways is necessary to develop a futuristic intervention to combat AD.
Indexed as
Identifiers
40824373What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.